Farmacologia clinica
Palivizumab: un anticorpo monoclonale umanizzato contro il virus respiratorio sinciziale
PALIVIZUMAB: A MONOCLONAL RSV ANTIBODY
LUCIANO DE SETA, GIUSEPPE ORSO
Divisione di Pediatria e Centro di Broncopneumologia e Allergologia, Ospedale “SS. Annunziata”, Napoli
Ottobre 1999 - pagg. 491 -494
Abstract
Respiratory Syncytial Virus (RSV) is the main cause of respiratory infections in the first
years of life. Preterm infants and those affected by broncopulmonary dysplasia (BPD) represent
the categories at highest risk of severe RSV infections. Palivizumab is a monoclonal
RSV antibody recently proposed for the prevention of RSV infections in at risk infants. The
Authors discuss the results of controlled trials. The cost/benefit profile of the preventive use
of palivizumab is not favorable and more studies are needed for evaluating the preventive
efficacy of palivizumab on the RSV related morbidity and mortality.
Parole chiave
Suggerite dall'AI
Classificazione MeSH
Bibliografia
Prophylactic administration of repiratory
syncytial virus immune globulin to high risk
infants and young children. NEJM 329, 1524-
30, 1993.
2. The Prevent Study Group: Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globuline prophylaxis. Pediatrics 99, 93-99, 1997.
3. American Academy of Pediatrics: Committee on Infectious Disease and Committee on Fetus and Newborn: Respiratory virus syncytial immune globulin intravenous: indications for use. Pediatrics 99, 645-9, 1997.
4. Simoes EAF, Sondheimer HM, Top FH, et al: Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital hearth disease. J Pediatr 133, 492- 9, 1998.
5. Meissner HC, Welliver RC, Chartrand SA, et al: Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Pediatr Infect Dis J 15, 1059-68, 1996.
6. Johnson S, Oliver C, Prince GA, et al: Development of a humanized nonoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176, 1215-24, 1997.
7. Meissner HC, Welliver RC, Chartrand SA, et al: Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Ped Inf Dis J 18, 223-31, 1999.
8. Saez-Llorens X, Castano E, Null D: Safety and pharmacokinetics of an intramuscolar humanized monoclonal antibody to respiratory syncytial virus in premature infants and in infants with bronchopulmonary dysplasia. Ped Inf Dis J 17, 787-91, 1998.
9. The IMpact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531-37, 1998.
10. Siva Knsubramanian, Weisman LE, Rodhes T: Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Ped Inf Dis J 17, 110-5, 1998.
11. American Academy of Pediatrics: Committee on Infectious Disease and Committee on Fetus and Newborn: Prevention of respiratory syncytial virus infection: indication for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 102, 1211-16, 1998.
12. Abman SH, Ogle W, Buttler-Simon N, et al: Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatrics 113, 826-30, 1988.
13. Cook RJ, Sackett DL: The number needed to treat: a clinically useful measure of treatment effect. BMJ 310, 452-54, 1995.
14. de Craen AJM, Vickers AJ, Tijssen JGP, et al: Number-needed-to-treat and placebocontrolled trials. Lancet 351, 310, 1998.
15. Storch GA: Humanized monoclonal antibody for prevention of respiratory syncytial virus infection. Pediatrics 102, 648-51, 1998.
16. Eppes SC: Question about palivizumab (Synagis). Pediatrics 103, 534, 1999.
17. Moler FW, Brown RW, Faix RG, et al: Comments on palivizumab (Synagis). Pediatrics 103, 495-6, 1999.
18. Lee SL, Robinson JL: Question about palivizumab (Synagis). Pediatrics 103, 535, 1999.
19. Zerr DM, Frenkel LM: Avances in antiviral therapy. Current opinion in Pediatrics 11, 21-7, 1999.
2. The Prevent Study Group: Reduction of respiratory syncytial virus hospitalization among premature infants and infants with bronchopulmonary dysplasia using respiratory syncytial virus immune globuline prophylaxis. Pediatrics 99, 93-99, 1997.
3. American Academy of Pediatrics: Committee on Infectious Disease and Committee on Fetus and Newborn: Respiratory virus syncytial immune globulin intravenous: indications for use. Pediatrics 99, 645-9, 1997.
4. Simoes EAF, Sondheimer HM, Top FH, et al: Respiratory syncytial virus immune globulin for prophylaxis against respiratory syncytial virus disease in infants and children with congenital hearth disease. J Pediatr 133, 492- 9, 1998.
5. Meissner HC, Welliver RC, Chartrand SA, et al: Prevention of respiratory syncytial virus infection in high risk infants: consensus opinion on the role of immunoprophylaxis with respiratory syncytial virus hyperimmune globulin. Pediatr Infect Dis J 15, 1059-68, 1996.
6. Johnson S, Oliver C, Prince GA, et al: Development of a humanized nonoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 176, 1215-24, 1997.
7. Meissner HC, Welliver RC, Chartrand SA, et al: Immunoprophylaxis with palivizumab, a humanized respiratory syncytial virus monoclonal antibody, for prevention of respiratory syncytial virus infection in high risk infants: a consensus opinion. Ped Inf Dis J 18, 223-31, 1999.
8. Saez-Llorens X, Castano E, Null D: Safety and pharmacokinetics of an intramuscolar humanized monoclonal antibody to respiratory syncytial virus in premature infants and in infants with bronchopulmonary dysplasia. Ped Inf Dis J 17, 787-91, 1998.
9. The IMpact-RSV Study Group: Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102, 531-37, 1998.
10. Siva Knsubramanian, Weisman LE, Rodhes T: Safety, tolerance and pharmacokinetics of a humanized monoclonal antibody to respiratory syncytial virus in premature infants and infants with bronchopulmonary dysplasia. Ped Inf Dis J 17, 110-5, 1998.
11. American Academy of Pediatrics: Committee on Infectious Disease and Committee on Fetus and Newborn: Prevention of respiratory syncytial virus infection: indication for the use of palivizumab and update on the use of RSV-IGIV. Pediatrics 102, 1211-16, 1998.
12. Abman SH, Ogle W, Buttler-Simon N, et al: Role of respiratory syncytial virus in early hospitalizations for respiratory distress of young infants with cystic fibrosis. J Pediatrics 113, 826-30, 1988.
13. Cook RJ, Sackett DL: The number needed to treat: a clinically useful measure of treatment effect. BMJ 310, 452-54, 1995.
14. de Craen AJM, Vickers AJ, Tijssen JGP, et al: Number-needed-to-treat and placebocontrolled trials. Lancet 351, 310, 1998.
15. Storch GA: Humanized monoclonal antibody for prevention of respiratory syncytial virus infection. Pediatrics 102, 648-51, 1998.
16. Eppes SC: Question about palivizumab (Synagis). Pediatrics 103, 534, 1999.
17. Moler FW, Brown RW, Faix RG, et al: Comments on palivizumab (Synagis). Pediatrics 103, 495-6, 1999.
18. Lee SL, Robinson JL: Question about palivizumab (Synagis). Pediatrics 103, 535, 1999.
19. Zerr DM, Frenkel LM: Avances in antiviral therapy. Current opinion in Pediatrics 11, 21-7, 1999.